https://www.pharmaceutical-technology.com/news/fda-boehringer-zongertinib-nsclc/ 2025-02-20T08:58:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/scientists-develop-largest-ever-biological-ai-model-that-thinks-in-nucleotides/ 2025-02-19T17:21:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/supernuss-stock-sinks-after-depression-drug-fails-trial/ 2025-02-19T16:46:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-moves-closer-to-selling-controlling-stake-in-17bn-valued-opella/ 2025-02-19T14:58:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cumberland-vibativ-china-nmpa/ 2025-02-19T14:32:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/amazon-joins-forces-with-memorial-sloan-kettering-for-ai-powered-drug-discovery/ 2025-02-19T11:56:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/glp-1ras-and-opioid-use-disorder-a-new-frontier-in-addiction-treatment/ 2025-02-21T20:57:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biogen-stoke-therapeutics-dravet-syndrome/ 2025-04-16T10:45:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/can-innovation-in-clinical-trial-delivery-meet-the-demands-of-increasing-complexity-in-drug-development/ 2025-03-06T17:58:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ceos-merck-kgaa-board/ 2025-02-19T08:58:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gileads-lenacapavir-moves-closer-to-fda-approval-for-hiv-prep-use/ 2025-02-18T18:07:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/valneva-hits-2024-sales-target-but-plans-lower-cash-burn-in-2025/ 2025-02-18T16:54:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-msd-welireg/ 2025-02-18T14:16:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-to-review-sanofi-regeneron-dupixent-sbla-for-bullous-pemphigoid/ 2025-02-18T11:17:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/hmri-novartis-australia-mou/ 2025-02-18T10:12:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-rznomics-rz-001/ 2025-02-18T09:03:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/onos-tgct-therapy-wins-fda-approval-challenging-daiichi-sankyo/ 2025-02-17T17:27:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/oncology-eclinical-solutions-adapting-to-the-challenges/ 2025-02-18T09:54:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/innates-lacutamab-fda-therapy/ 2025-02-17T12:07:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bispecific-antibody-startup-bambusa-raises-90m-to-fund-clinical-trials/ 2025-02-17T12:00:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bavarian-nordic-scoops-fda-approval-for-chikungunya-vaccine-in-adults-and-teens/ 2025-02-17T11:40:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsks-penmenvy-fda-approval/ 2025-02-17T10:34:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/moderna-decline-q4-2024/ 2025-02-17T08:26:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/csl-ec-andembry-hae/ 2025-02-14T14:41:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/dmd-market-grow-7mm-2033/ 2025-02-14T14:31:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/galderma-enters-fierce-european-atopic-dermatitis-market-with-nemluvio-approval/ 2025-02-14T11:55:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/eu-reshapes-htas-is-the-industry-ready-for-it/ 2025-02-14T10:56:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/newleos-93-5m-neuropsychiatric-disorders/ 2025-02-14T10:45:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/health-canada-novartis-fabhalta/ 2025-02-14T08:33:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/revolutionary-approaches-to-drug-design-how-ai-is-transforming-life-sciences/ 2025-02-14T11:57:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/aardvark-prices-94-2m-ipo-to-fund-development-of-prader-willi-syndrome-drug/ 2025-02-13T17:16:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/trump-presidency-downturn-nih-sbir-sttr-grant-funding/ 2025-02-13T15:44:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/smartcella-cell-therapy-parkinsons/ 2025-02-13T14:20:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/us-government-actions-having-a-serious-impact-on-global-health-who-chief-says/ 2025-02-13T11:54:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/royalty-pharma-pays-250m-for-rights-to-biogens-lupus-drug/ 2025-02-13T11:33:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/trinetx-fujitsu-jv-japan/ 2025-02-13T11:17:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-xilio-immunotherapies/ 2025-02-13T08:17:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abcuro-secures-200m-as-it-eyes-approval-for-rare-muscle-disease-drug/ 2025-02-13T05:43:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-surpasses-us-for-annual-trials/ 2025-02-12T16:29:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lundbeck-msa-amlenetug/ 2025-02-12T14:21:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-gomekli-as-first-neurofibromatosis-drug-for-adults/ 2025-02-12T11:30:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/travere-takes-rare-disease-kidney-drug-to-fda-despite-failed-trial/ 2025-02-12T11:00:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-bridgebio-attr-cm/ 2025-02-12T10:40:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/health-canada-msd-keytruda/ 2025-02-12T08:19:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/how-to-better-engage-clinical-trial-sites/ 2025-02-11T20:47:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-awards-82-6m-to-ai-drug-discovery-companies/ 2025-02-11T17:35:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/who-and-st-jude-start-distributing-paediatric-cancer-medicines-amid-us-aid-cuts/ 2025-02-11T16:23:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/grace-15m-gtx-104/ 2025-02-11T14:26:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eli-lilly-pledges-630m-on-olixs-phase-i-rna-candidate-for-mash/ 2025-02-11T11:42:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-anthos-925m-upfront/ 2025-02-11T10:40:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/obesity-market-173-5-billion-2031/ 2025-02-12T20:36:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bio-thera-intas-biosimilar/ 2025-02-11T08:28:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/public-health-strategies-skip-patients-with-rare-diseases-says-uk-study/ 2025-02-10T19:21:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nmpa-keymed-stapokibart-rhinitis/ 2025-02-10T14:26:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fourth-person-receives-egenesis-gene-edited-pig-kidney-transplant/ 2025-02-10T11:49:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/super-bowl-ad-for-copycat-weight-loss-drugs-stokes-pharma-power-debate/ 2025-02-10T12:27:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eton-patent-diabetes-insipidus/ 2025-02-10T11:11:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-abbvie-emblaveo-intra-abdominal-infections/ 2025-02-10T08:37:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bain-capital-buys-mitsubishi-tanabe-pharma-for-3-3bn/ 2025-02-07T19:39:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/proposed-us-tariffs-impact/ 2025-02-12T11:21:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-increases-ownership-stake-partaking-in-pharma-buyback-trend/ 2025-02-07T16:40:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/alumis-acelyrin-agreement-merge/ 2025-02-07T14:44:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/43rd-annual-jp-morgan-healthcare-conference-2025/ 2025-02-13T20:11:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-spoken-revolution-in-rater-training-assessment/ 2025-02-26T14:02:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/genentech-eyes-lupus-market-for-gazyva-with-positive-phase-iii-data-readout/ 2025-02-07T11:32:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-ai-is-streamlining-cell-and-gene-therapy-manufacturing/ 2025-02-07T11:00:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/relmada-ts-rights-asarina/ 2025-02-07T10:47:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/treating-alcohol-addiction-filling-the-medication-gap/ 2025-02-07T10:44:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/dr-reddys-henlius-hlx15/ 2025-02-07T08:43:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazenecas-shares-rise-as-it-addresses-china-investigation/ 2025-02-06T20:15:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-nordisk-plans-new-study-for-cagrisema-targets-2026-submission/ 2025-02-07T10:18:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-arbor-biotechnologies-ph1/ 2025-02-06T14:47:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/supernus-wins-fda-approval-for-parkinsons-pump-on-fourth-try/ 2025-02-06T11:49:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/tripartite-mou-mrna/ 2025-02-06T11:23:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uspto-patent-vistagen-neuropathic/ 2025-02-06T09:21:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/x-elio-partners-with-pharmaceutical-programme-for-10-year-solar-ppa/ 2025-02-05T19:24:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/valnevas-chikungunya-vaccine-wins-uk-approval/ 2025-02-05T16:56:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/supply-chains-and-ai-take-precedence-at-european-clinical-trial-meeting/ 2025-02-05T16:16:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-stays-optimistic-on-vaccines-amidst-us-and-china-woes/ 2025-02-05T16:16:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astellas-ga-treatment-japan/ 2025-02-05T15:03:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/trump-tariffs-could-strain-medicine-supply-and-drive-drug-costs/ 2025-02-05T17:35:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/driving-innovation-respiratory-health-areteias-2025-milestones-future-goals/ 2025-02-05T11:04:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/humphries-medpharm-ceo/ 2025-02-05T10:38:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jabil-acquires-cdmo-pii/ 2025-02-05T09:42:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/radiopharmaceutical-deals-drive-sector-growth-despite-supply-crisis/ 2025-03-03T10:19:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/italian-charity-seeks-ema-approval-for-rescued-gene-therapy/ 2025-02-05T14:39:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/thermo-fisher-continues-viral-vector-withdrawal-lays-off-300-employees/ 2025-02-04T17:49:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/usc-gene-therapy-glioblastoma/ 2025-02-04T14:58:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/immunotherapeutic-responses-and-their-assessments/ 2025-02-19T16:10:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/world-cancer-day-who-warns-of-rising-cancer-burden-in-southeast-asia/ 2025-02-04T11:54:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vanda-anaptysbio-deal-gpp/ 2025-02-04T10:38:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/microplastics-silent-threat/ 2025-02-04T09:55:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-imfinzi-eu/ 2025-02-04T16:14:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/interviews/people-focused-cancer-care-demands-policy-support/ 2025-05-01T08:11:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/advancell-raises-112m-as-radiopharma-buzz-continues/ 2025-02-03T20:41:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-seeks-input-on-new-regulatory-guidance-for-cancer-vaccines/ 2025-02-03T20:26:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizers-colon-cancer-combo-approval-further-supported-by-phase-iii-win/ 2025-02-03T17:10:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/celltrion-avtozma-fda-approval/ 2025-02-03T13:24:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-kicks-off-share-buyback-plan-with-3bn-loreal-stake-purchase/ 2025-02-03T11:43:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-sarclisa-combo-china/ 2025-02-03T10:43:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-viiv-jj-hiv-1/ 2025-02-03T08:30:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-recommends-bavarian-nordics-chikungunya-vaccine-for-adults-and-teenagers/ 2025-01-31T21:17:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/rentschler-closes-uk-cell-and-gene-therapy-facility-and-does-a-pivot-to-biologics/ 2025-02-03T14:26:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/roche-targets-continued-growth-after-strong-2024-sales/ 2025-01-31T05:06:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/all-change-germany-confidential-pricing-irp/ 2025-01-31T17:34:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-q4-2024-833m/ 2025-01-31T15:25:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/top-20-biopharma-market-caps-2024-policy/ 2025-01-31T13:47:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nhs-england-to-offer-casgevy-for-sickle-cell-disease-patients/ 2025-02-05T14:13:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/okuzawa-daiichi-sankyo-ceo/ 2025-02-03T09:55:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-vertex-pain-journavx/ 2025-01-31T08:36:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/rfk-china-manufacturing-drug-concern/ 2025-01-31T09:48:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-launches-refreshed-ilap-to-speed-up-nhs-drug-access/ 2025-01-30T17:26:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/takeda-julie-kim-ceo/ 2025-01-30T14:14:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/whos-neglected-tropical-disease-day-at-unfamiliar-odds-with-us-stance/ 2025-01-30T11:46:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/leveragen-moonlight-bio-t-cell/ 2025-01-30T10:36:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/acellera-psivant-drug-discovery/ 2025-01-30T08:20:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lyndra-sayer-ceo-president/ 2025-01-29T15:35:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-expands-enhertu-approval-to-include-her2-ultralow-breast-cancer-patients/ 2025-01-30T12:21:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lantheus-acquires-radiopharma-cdmo-evergreen-for-up-to-1bn/ 2025-01-29T16:32:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-nordisk-secures-fda-approval-for-ozempic-in-diabetes-with-ckd/ 2025-01-29T11:39:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sonnet-eu-fhab-technology/ 2025-01-29T11:07:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/will-european-pfas-ban-disrupt-pharma-supply-chains/ 2025-01-30T15:01:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-rmat-beacon-xlrp/ 2025-01-29T15:11:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/allakos-cuts-75-of-workforce-after-chronic-hives-trial-failure/ 2025-01-28T17:41:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/itms-radiotherapeutic-beats-out-standard-of-care-in-phase-iii-trial/ 2025-01-28T18:14:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/glp-1ra-developer-metsera-targets-289m-ipo/ 2025-01-28T17:27:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/can-fite-patent-namodenoson/ 2025-01-28T14:30:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sage-rejects-biogens-469m-takeover-bid/ 2025-01-28T11:28:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ab2-nippon-tadekinig-alfa/ 2025-01-28T10:44:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/ai-driven-virtual-cgm-data-t1d/ 2025-01-28T10:06:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/arena-international-outsourcing-clinical-trials-west-coast/ 2025-01-28T12:30:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-oxford-cancer-vaccine/ 2025-01-28T08:05:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-settles-biohaven-kickback-claims-case-for-59-7m/ 2025-01-27T15:22:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/msd-wins-fda-priority-review-for-welireg-in-rare-endocrine-cancer/ 2025-01-27T15:04:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/the-ai-advantage-in-discovering-new-medicines/ 2025-01-27T14:36:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/tevogen-microsoft-advance-predictcell/ 2025-01-27T14:02:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/buyers-guide/strategic-intelligence-pharma/ 2025-11-05T11:43:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bia-report-uk-biotech-investment-surged-to-3-5bn-in-2024/ 2025-01-30T12:19:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-eisai-biogen-leqembi/ 2025-01-27T17:17:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/trying-times-for-biopharmaceuticals-how-researchers-can-flourish-amid-industry-challenges/ 2025-01-27T09:21:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/amgen-facility-north-carolina/ 2025-01-27T08:16:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ascentage-pharma-raises-126m-in-first-biotech-ipo-of-2025/ 2025-01-24T17:49:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/purdue-and-sackler-family-agree-to-7-4bn-national-opioid-settlement/ 2025-01-24T17:18:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-lupin-heart-therapy/ 2025-01-24T14:22:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/podcast-adaptive-logistics-in-a-changing-clinical-landscape/ 2025-07-15T11:14:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/stealth-faces-another-hurdle-as-fda-delays-decision-on-barth-syndrome-drug/ 2025-01-24T11:04:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/emcure-rd-gujarat-india/ 2025-01-24T10:44:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-neomorph-glue-degraders/ 2025-01-24T08:01:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/excellence-awards/excellence-awards-2024-winners-announced/ 2025-01-22T14:32:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/magazine-the-biggest-challenges-clinical-trials-will-face-in-2025/ 2025-01-23T16:55:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biogens-higher-dose-spinraza-under-review-by-us-and-eu-regulators/ 2025-01-23T16:07:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/bladder-cancer-shaping-the-future-of-global-clinical-trials/ 2025-01-24T09:20:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-zai-lung-cancer/ 2025-01-30T12:16:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/emergent-seeking-reverse-fortunes-become-major-overdose-treatment-player/ 2025-01-23T13:01:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/disc-raises-225-5m-as-it-eyes-approval-of-rare-skin-disorder-drug/ 2025-01-23T12:28:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-adds-boxed-warning-to-multiple-sclerosis-drugs-after-anaphylaxis-cases/ 2025-01-23T11:44:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/comprehensive-epcm-services/ 2025-01-27T17:26:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cellipont-secretome-cellular-therapy/ 2025-01-23T10:44:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/viralgen-axovia-gene-therapy/ 2025-01-23T08:34:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/excellence-awards/featured-company/2024-catalent/ 2025-04-15T08:35:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-gains-nice-nod-for-lung-cancer-drugs-tagrisso-and-imfinzi/ 2025-01-22T16:48:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/glox-antibiotics-cystic-fibrosis/ 2025-01-22T15:12:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ataras-t-cell-programmes-hit-with-clinical-hold-after-third-party-site-woes/ 2025-01-29T11:21:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jjs-spravato-receives-fda-label-expansion-for-depression-monotherapy/ 2025-01-22T11:41:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-100bn-frontier-untapped-potential-in-animal-health-innovation/ 2025-01-24T09:29:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-bluejay-chd-brelovitug/ 2025-01-22T10:06:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/catalent-galapagos-car-t/ 2025-01-22T08:42:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nvidia-champions-innophore-partnership-to-model-drug-dynamics-with-ai/ 2025-01-21T21:29:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ais-potential-in-the-womens-health-exciting-says-gates-foundation-leader/ 2025-01-22T13:11:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/buyers-guide/lead-generation-providers-technology/ 2025-11-05T11:43:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jjs-lazcluze-rybrevant-combination-obtains-european-approval-to-treat-nsclc/ 2025-01-22T14:49:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/junshi-leo-pharma-toripalimab/ 2025-01-21T14:29:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/buyers-guide/sales-enablement-prospecting-automation/ 2025-11-06T19:56:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/buyers-guide/active-pharmaceutical-ingredients/ 2025-11-05T11:44:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cepi-first-mrna-based-rift-valley-fever-vaccine/ 2025-01-21T11:50:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/streamlining-mesenchymal-stem-cell-msc-expansion/ 2025-01-21T11:45:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/trump-signs-executive-order-to-leave-world-health-organization/ 2025-01-21T11:35:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/fda-review-designations-innovation/ 2025-01-21T11:13:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/health-canada-takeda-capsules/ 2025-01-21T10:46:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-gsk-endometrial-cancer/ 2025-01-21T08:36:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/moderna-hhs-mrna-influenza-vaccines/ 2025-01-21T15:54:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/keymed-partners-with-us-based-biotech-prolium-in-bispecific-antibody-deal/ 2025-01-20T16:12:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/fda-start-cogent-pilot-programmes/ 2025-01-20T16:10:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/interleukin-inhibitors-dermatology/ 2025-01-20T14:14:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/buyers-guide/account-intent-based-sales-marketing/ 2025-11-05T11:45:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/arrowhead-plozasiran-set-for-fda-review-as-tryngolza-challenge-looms/ 2025-01-20T11:58:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-secures-first-btk-approval-in-first-line-mcl/ 2025-01-20T11:54:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/feinstein-institutes-nih-ghrelin/ 2025-01-20T11:05:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/buyers-guide/sales-marketing-intent-data/ 2025-11-05T11:45:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/amgens-combo-fda-colorectal-cancer/ 2025-02-05T19:58:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/jpm-2025-lonza-shares-outlook-on-chi-exit-and-acquisition-strategy/ 2025-01-17T19:04:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/shionogi-awarded-375m-from-hhs-for-preventative-covid-19-injectable/ 2025-01-17T18:23:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/impact-ovarian-cancer-china/ 2025-01-17T15:29:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ozempic-named-in-latest-medicare-price-negotiations/ 2025-01-17T18:13:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-believes-in-the-metaverse-will-healthcare-thaw-the-technologys-winter-2/ 2025-01-23T11:28:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/heor-explained-improving-healthcare-decisions-with-real-world-evidence/ 2025-06-19T08:15:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/mega-m-and-a-jp-morgan-conference-2025/ 2025-01-17T11:38:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/charles-river-akron-cell-therapy/ 2025-01-17T11:22:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-beats-ema-to-most-approved-new-drugs-in-2024/ 2025-01-17T11:02:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/copd-market-astrazeneca-ortfolio-growth/ 2025-01-17T10:58:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/buyers-guide/sales-marketing-intelligence/ 2025-11-05T11:46:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/innovent-ibi343-pancreatic-cancer/ 2025-01-17T08:26:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/nothing-to-do-with-geopolitics-wuxi-biologics-ceo-bullish-in-face-of-biosecure/ 2025-01-16T22:21:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/jpm-2025-wuxi-apptec-rebuffs-concern-about-lower-glp-1-demand-after-lillys-low-revenue-forecast/ 2025-01-16T21:57:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jp-morgan-2025-radiopharmaceuticals-mna-fuels-telixs-busy-year/ 2025-01-16T19:41:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/european-supergroup-launches-to-tackle-diversity-in-clinical-trials/ 2025-01-16T16:55:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/santhera-launches-dmd-therapy-in-the-uk-following-nice-nod/ 2025-01-16T16:16:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/meridian-medical-wins-129m-us-gov-contract-for-nerve-agent-antidote-supply/ 2025-01-16T16:35:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lyndra-thermo-fisher-oral-therapies/ 2025-01-16T15:06:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/inflarx-wins-eu-approval-for-gohibic-in-covid-19-induced-ards/ 2025-01-16T15:05:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jp-morgan-2025-goodrx-takes-aim-at-us-drug-pricing-challenges/ 2025-01-16T11:37:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/designing-clinical-trials-for-a-complex-disease-pediatric-obesity/ 2025-01-17T08:56:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/be-bio-92m-haemophilia-hypophosphatasia/ 2025-01-16T10:34:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lilly-fda-omvoh-crohns/ 2025-01-16T08:05:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jp-morgan-2025-abbvie-counts-on-skyrizi-and-rinvoq-to-fill-humira-sized-hole/ 2025-01-15T23:33:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/charles-river-ceo-reveals-drop-in-2025-revenue-outlook-at-jp-morgan/ 2025-01-15T20:13:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/regenxbio-and-nippon-shinyaku-forge-810m-gene-therapy-deal/ 2025-01-22T15:00:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jp-morgan-2025-astrazeneca-promises-a-catalyst-rich-year-ahead/ 2025-01-15T18:58:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/insmed-gene-therapy-dmd-challenge-landscape/ 2025-01-15T16:31:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-simcere-zaiming-trispecific-antibody/ 2025-01-15T14:47:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jp-morgan-2025-incyte-expects-period-of-defining-catalysts/ 2025-01-15T13:00:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/zetas-integrated-approach/ 2025-01-23T11:20:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/who-reports-eight-deaths-from-suspected-marburg-outbreak-in-tanzania/ 2025-01-15T12:14:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jp-morgan-2025-eli-lilly-misses-2024-revenue-estimate-by-400m/ 2025-01-15T11:32:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/acadia-rett-syndrome-therapy/ 2025-01-15T11:07:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-a-fresh-approach-to-supply-chains-can-unlock-scaling-in-personalized-medicine/ 2025-01-15T11:01:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/stelara-j-and-j-immunology-strategy/ 2025-01-15T09:36:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/umoja-100m-car-t/ 2025-01-15T09:02:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/jpm-2025-thermo-fisher-very-positive-on-sterile-demand-as-catalent-takes-capacity-out-of-market/ 2025-01-15T20:29:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/jp-morgan-2025-almirall-updates-strategy-with-focus-on-medical-dermatology/ 2025-01-15T03:50:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jp-morgan-2025-novartis-streamlines-its-portfolio-to-drive-future-growth/ 2025-01-17T09:18:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/daiichi-sankyo-buys-solid-tumour-adc-from-glycotope-for-132-5m/ 2025-01-14T18:39:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jp-morgan-2025-moderna-stock-suffers-after-ceo-reveals-conservative-2025-guidance/ 2025-01-14T17:31:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/clinical-research-survey-results-the-key-pressures-for-smes-and-business-outlook/ 2025-01-14T16:58:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/j-and-j-intra-cellular-therapies-neurology/ 2025-01-14T16:13:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/pharma-prices-more-than-250-drugs-us-january-2025/ 2025-01-14T16:10:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eisai-and-biogens-subcutaneous-leqembi-set-for-fda-review/ 2025-01-14T12:06:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/normunity-raises-75m-to-advance-solid-tumour-targeting-t-cell-engagers/ 2025-01-14T11:40:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jp-morgan-amgen-maritide-paves-way-obesity/ 2025-01-14T11:21:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/enhancing-patient-engagement-and-outcomes-in-the-nhs/ 2025-01-14T13:06:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/excellence-awards/featured-company/2024-image-analysis-group/ 2025-01-22T07:42:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/excellence-awards/featured-company/2024-iff-pharma-solutions/ 2025-01-22T07:42:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/excellence-awards/featured-company/2024-syngene/ 2025-01-22T07:43:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eli-lilly-targets-scorpion-therapeutics-to-expand-reach-in-oncology/ 2025-01-13T23:33:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-outlines-pipeline-reshuffle-and-capital-reallocation-at-jp-morgan-2025/ 2025-01-14T12:58:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biogen-proposes-acquisition-of-partner-sage-therapeutics/ 2025-01-13T19:14:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gilead-leo-stat6-inflammatory/ 2025-01-13T14:49:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jp-morgan-2025-nvidia-partners-with-iqvia-illumina-and-mayo-clinic/ 2025-01-13T14:21:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/small-matter-big-challenges-nano-milling-in-a-sterilised-environment/ 2025-01-13T12:14:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/johnson-johnson-intra-cellular-therapies/ 2025-01-13T14:02:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jp-morgan-2025-gsk-acquires-idrx-in-1-15bn-deal/ 2025-01-13T11:24:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/promising-future-regenerative-medicine/ 2025-01-13T10:47:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mediar-deal-lilly-ipf/ 2025-01-13T08:42:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/intellia-slashes-workforce-by-27-to-focus-on-late-stage-crispr-candidates/ 2025-01-15T11:24:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-cder-director-patrizia-cavazzoni-announces-resignation/ 2025-01-10T18:06:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/alzheimers-total-prevalent-cases-to-reach-22-51-million-in-8mm-in-2033/ 2025-01-10T17:28:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/climb-bio-mabworks-clym116/ 2025-01-10T15:04:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/a2-biotherapeutics-raises-80m-to-advance-car-t-therapies-for-solid-tumours/ 2025-01-10T11:48:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/light-horse-emerges-with-62m-and-novartis-partnership-worth-up-to-1bn/ 2025-01-10T22:06:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/coave-funding-aligater-platform/ 2025-01-10T11:09:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/newron-myung-in-evenamide/ 2025-01-10T08:51:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/synaffix-secures-adc-deals-with-boehringer-and-mitsubishi-tanabe/ 2025-01-10T03:19:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/samsung-biologics-ligachem-adc/ 2025-01-13T17:33:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-based-verdiva-launches-with-410m-and-an-oral-glp-1ra-candidate/ 2025-01-09T11:54:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/palforzia-peanut-allergy-treatment-use-in-europe-expanded-to-toddlers/ 2025-01-09T11:46:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/aspect-secures-115m-funds/ 2025-01-09T10:59:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-nordisk-valo-cardiometabolic-drugs/ 2025-01-09T08:52:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-taps-alloy-therapeutics-for-cns-antisense-drug-development/ 2025-01-08T17:16:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/clinical-trial-trends-in-2025-investment-headwinds-wearables-and-targeted-ai-uses/ 2025-05-27T16:41:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-nmpa-msd-hpv-vaccine/ 2025-01-08T15:17:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/chugai-and-araris-enter-780m-adc-research-collaboration/ 2025-01-13T17:40:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vertex-and-orna-sign-partnership-to-improve-efficiencies-of-gene-therapies/ 2025-01-15T11:20:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/actuates-pancreatic-cancer-ema/ 2025-01-08T11:05:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/calls-for-increased-education-and-support-for-sickle-cell-blood-therapy-in-us/ 2025-01-09T11:55:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-fda-breakthrough-osteosarcoma/ 2025-01-13T17:38:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/acelyrin-stock-plunges-after-positive-phase-ii-data-readout-in-thyroid-eye-disease/ 2025-01-08T10:53:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/variant-novo-metabolic-disease/ 2025-01-07T14:08:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/candid-therapeutics-signs-925m-t-cell-engager-deal-with-wuxi-biologics/ 2025-01-09T11:09:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/wuxi-biologics-to-sell-ireland-based-vaccine-site-to-msd-for-500m/ 2025-01-07T11:10:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-sentynl-menkes-nda/ 2025-01-07T10:59:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-tempest-hepatocellular-carcinoma/ 2025-01-07T09:18:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/covid-19-the-global-clinical-trial-landscape-in-2024/ 2025-01-07T09:18:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/danish-biotech-orbis-secures-94m-to-develop-oral-versions-of-biologics/ 2025-01-06T15:24:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-nmd-charcot-marie-tooth/ 2025-01-06T13:36:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ultragenyxs-evkeeza-secures-eu-approval-for-young-children-with-rare-cholesterol-disorder/ 2025-01-06T12:07:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/amgens-imdylltra-wins-conditional-mhra-licence-for-lung-cancer/ 2025-01-06T11:43:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/heart-failure-market-pipeline-agents-unmet-needs/ 2025-01-06T11:14:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/adscc-clinical-grade-ipscs/ 2025-01-06T10:21:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nmpa-gsk-nucala-crswnp/ 2025-01-06T09:36:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-325-biontech-malignant-mesothelioma-likelihood-of-approval/ 2025-01-06T02:05:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/coronavirus-disease-2019-covid-19-vaccine-china-national-biotec-group-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2025-01-07T13:45:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosigotifator-calico-life-sciences-unspecified-central-nervous-system-disorders-likelihood-of-approval/ 2025-01-06T02:05:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-innoup-farma-solid-tumor-likelihood-of-approval/ 2025-01-06T02:05:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nmda-regulator-boehringer-ingelheim-international-unspecified-central-nervous-system-disorders-likelihood-of-approval/ 2025-01-06T02:05:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-cd22-car-t-cells-shanghai-biomed-union-biotechnology-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2025-01-06T02:05:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hlc-001-human-life-cord-japan-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2025-01-06T02:05:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gcc-4001-artiva-biotherapeutics-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-06T02:04:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-rezetecan-jiangsu-hengrui-medicine-cervical-cancer-likelihood-of-approval/ 2025-01-06T02:04:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lr-19155-lg-chem-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-06T02:04:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bivamelagon-rhythm-pharmaceuticals-obesity-likelihood-of-approval/ 2025-01-06T02:04:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gcc-4001-artiva-biotherapeutics-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-06T02:04:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/moma-313-moma-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-06T02:04:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/moma-313-moma-therapeutics-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-06T02:04:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bat-8006-bio-thera-solutions-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-06T02:04:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/met-3-nubiyota-hypertriglyceridemia-likelihood-of-approval/ 2025-01-06T02:04:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/srd-002-sardocor-diastolic-heart-failure-hfpef-likelihood-of-approval/ 2025-01-06T02:04:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/covid-19-omicron-jn-1-vaccine-moderna-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-06T02:04:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bg-102-sl-bigen-obesity-likelihood-of-approval/ 2025-01-06T02:04:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hrs-1167-merck-castration-resistant-prostate-cancer-crpc-likelihood-of-approval/ 2025-01-06T02:04:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hrs-1167-merck-ovarian-cancer-likelihood-of-approval/ 2025-01-06T02:03:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosfomycin-metronidazole-reponex-pharmaceuticals-colon-cancer-likelihood-of-approval/ 2025-01-06T02:03:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dapagliflozin-propanediol-metformin-hydrochloride-er-yooyoung-pharm-type-2-diabetes-likelihood-of-approval/ 2025-01-06T02:03:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amt-676-multitude-therapeutics-neuroendocrine-tumors-likelihood-of-approval/ 2025-01-06T02:03:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-admsc-allogeneic-hope-biosciences-post-acute-sequelae-of-covid-2019-pasc-or-long-covid-likelihood-of-approval/ 2025-01-06T02:03:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/coronavirus-disease-2019-covid-19-alpha-beta-bivalent-vaccine-sinocelltech-group-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-06T02:03:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/am-3101-amplicore-unspecified-musculoskeletal-disorders-likelihood-of-approval/ 2025-01-06T02:03:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cln-619-cullinan-therapeutics-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-06T02:03:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abx-002-autobahn-therapeutics-major-depressive-disorder-likelihood-of-approval/ 2025-01-06T02:03:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/partnered-liquid-tumor-1-isogenica-hematological-tumor-likelihood-of-approval/ 2025-01-06T02:03:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nxe-0048149-nxera-pharma-psychosis-likelihood-of-approval/ 2025-01-06T02:03:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iluzanebart-vigil-neuroscience-unspecified-neurologic-disorders-likelihood-of-approval/ 2025-01-06T02:03:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dr-10627-zhejiang-doer-biologics-diabetes-likelihood-of-approval/ 2025-01-06T02:03:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tca-101-tcr-cure-biopharma-technology-endometrial-cancer-likelihood-of-approval/ 2025-01-06T02:03:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07921585-pfizer-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-06T02:02:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/semaglutide-biosimilar-leto-laboratories-diabetes-likelihood-of-approval/ 2025-01-06T02:02:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bjtj-0003-beijing-tuojie-biomedical-technology-thrombosis-likelihood-of-approval/ 2025-01-06T02:02:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ips-cell-derived-natural-killer-ink-cells-icamuno-biotherapeutics-ovarian-cancer-likelihood-of-approval/ 2025-01-06T02:02:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bempikibart-q32-bio-inflammation-likelihood-of-approval/ 2025-01-06T02:02:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/coronavirus-disease-2019-sars-cov-2-vaccine-shionogi-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-06T02:02:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6540-f-hoffmann-la-roche-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-06T02:02:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nyprg-101-ceruvia-lifesciences-alcohol-dependence-likelihood-of-approval/ 2025-01-06T02:02:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incb-123667-incyte-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-06T02:02:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incb-123667-incyte-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-06T02:02:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07832837-pfizer-asthma-likelihood-of-approval/ 2025-01-06T02:02:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vi-0810-vivus-diabetes-likelihood-of-approval/ 2025-01-06T02:02:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-5492-astrazeneca-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-06T02:02:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/na-731-biomed-industries-traumatic-brain-injury-likelihood-of-approval/ 2025-01-06T02:02:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kls-1-vector-vitale-metastatic-melanoma-likelihood-of-approval/ 2025-01-06T02:01:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bm-219-suzhou-biomissile-biopharmaceutical-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-06T02:01:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shra-1921-jiangsu-hengrui-medicine-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-06T02:01:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yh-013-eucure-beijing-biopharma-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-06T02:01:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ortho-r-chitogenx-unspecified-musculoskeletal-disorders-likelihood-of-approval/ 2025-01-06T02:01:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tca-101-tcr-cure-biopharma-technology-solid-tumor-likelihood-of-approval/ 2025-01-06T02:01:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbt-004-cloudbreak-therapeutics-unspecified-ophthalmological-disorders-likelihood-of-approval/ 2025-01-06T02:01:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tak-861-takeda-pharmaceutical-narcolepsy-likelihood-of-approval/ 2025-01-06T02:01:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuv-868-nuvation-bio-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-06T02:01:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incb-123667-incyte-peritoneal-cancer-likelihood-of-approval/ 2025-01-06T02:01:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incb-123667-incyte-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-06T02:01:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07867246-pfizer-unspecified-influenza-virus-infections-likelihood-of-approval/ 2025-01-06T02:01:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aga-2118-angitia-biopharmaceuticals-post-menopausal-osteoporosis-likelihood-of-approval/ 2025-01-06T02:01:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-cdh17-car-t-cells-utc-therapeutics-pancreatic-cancer-likelihood-of-approval/ 2025-01-06T02:00:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-cdh17-car-t-cells-utc-therapeutics-colorectal-cancer-likelihood-of-approval/ 2025-01-06T02:00:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hm-0021005-er-hua-medicine-shanghai-type-2-diabetes-likelihood-of-approval/ 2025-01-06T02:00:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/clph-291-cellphire-wiskott-aldrich-syndrome-likelihood-of-approval/ 2025-01-06T02:00:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kamuvudine-9-inflammasome-therapeutics-graves-ophthalmopathy-likelihood-of-approval/ 2025-01-06T02:00:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alm-412-almirall-familial-adenomatous-polyposis-likelihood-of-approval/ 2025-01-06T01:59:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/covax-19-vaxine-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-06T01:59:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/edp-235-enanta-pharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-06T01:59:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zurletrectinib-innocare-pharma-central-nervous-system-cns-tumor-likelihood-of-approval/ 2025-01-06T01:59:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/macupatide-eli-lilly-and-co-type-2-diabetes-likelihood-of-approval/ 2025-01-06T01:59:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tev-56278-teva-pharmaceutical-industries-solid-tumor-likelihood-of-approval/ 2025-01-06T01:59:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shra-2009-jiangsu-hengrui-medicine-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-06T01:59:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imc-2034-immunecyte-premature-ovarian-failure-likelihood-of-approval/ 2025-01-06T01:59:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alta-2618-alterome-therapeutics-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-06T01:59:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sytalizumab-beijng-immunoah-pharma-tech-solid-tumor-likelihood-of-approval/ 2025-01-06T01:59:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inf-904-inflarx-chronic-urticaria-or-hives-likelihood-of-approval/ 2025-01-06T01:59:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alphaf-001-alpha-fusion-follicular-thyroid-cancer-likelihood-of-approval/ 2025-01-06T01:59:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trb-051-trex-bio-inflammation-likelihood-of-approval/ 2025-01-06T01:59:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-6837-merck-solid-tumor-likelihood-of-approval/ 2025-01-06T01:59:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biolink-2018-protheragen-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2025-01-06T01:58:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ev68-228-n-kbio-enterovirus-infections-likelihood-of-approval/ 2025-01-06T01:58:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ar-17043-alcon-ocular-hypertension-likelihood-of-approval/ 2025-01-06T01:58:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/np-028-emergent-biosolutions-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-06T01:58:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-10188-beigene-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-06T01:58:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osemitamab-transcenta-lung-cancer-likelihood-of-approval/ 2025-01-06T01:58:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-pamirtecan-biontech-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-06T01:58:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-pamirtecan-biontech-solid-tumor-likelihood-of-approval/ 2025-01-06T01:58:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/flonoltinib-maleate-chengdu-zenitar-biomedical-technology-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-06T01:58:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trecondyv-medac-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-06T01:58:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrt-6160-monte-rosa-therapeutics-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-06T01:58:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/smp-3124-sumitomo-pharma-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-06T01:58:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vxs-1219-vaxxas-influenza-a-virus-h7n9-subtype-infections-likelihood-of-approval/ 2025-01-06T01:58:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yts-109-bristar-immunotech-biotechnology-dermatomyositis-likelihood-of-approval/ 2025-01-06T01:58:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yts-109-bristar-immunotech-biotechnology-polymyositis-likelihood-of-approval/ 2025-01-06T01:57:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zolacabtagene-autoleucel-bristol-myers-squibb-relapsing-multiple-sclerosis-rms-likelihood-of-approval/ 2025-01-06T01:57:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zolacabtagene-autoleucel-bristol-myers-squibb-primary-progressive-multiple-sclerosis-ppms-likelihood-of-approval/ 2025-01-06T01:57:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-gene-therapy-indapta-therapeutics-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-06T01:57:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enb-105-ennovabio-inflammatory-bowel-disease-likelihood-of-approval/ 2025-01-06T01:57:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-4101174-eli-lilly-and-co-cervical-cancer-likelihood-of-approval/ 2025-01-06T01:57:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/palonosetron-hydrochloride-la-lp-pharmaceutical-xiamen-chemotherapy-induced-nausea-and-vomiting-likelihood-of-approval/ 2025-01-06T01:57:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prime-msk-shot-thomas-advanced-medical-unspecified-cardiovascular-disorders-likelihood-of-approval/ 2025-01-06T01:57:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onc-841-oncoc4-solid-tumor-likelihood-of-approval/ 2025-01-06T01:57:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrt-6160-monte-rosa-therapeutics-multiple-sclerosis-likelihood-of-approval/ 2025-01-06T01:57:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abi-110-avirmax-polypoidal-choroidal-vasculopathy-likelihood-of-approval/ 2025-01-06T01:56:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hpv-induced-cancers-theravectys-human-papillomavirus-hpv-associated-cancer-likelihood-of-approval/ 2025-01-06T01:56:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imm-27m-immuneonco-biopharmaceuticals-shanghai-breast-cancer-likelihood-of-approval/ 2025-01-06T01:55:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yts-109-bristar-immunotech-biotechnology-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-anca-vasculitis-likelihood-of-approval/ 2025-01-06T01:55:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/c3-binding-polypeptide-boehringer-ingelheim-international-unspecified-ophthalmological-disorders-likelihood-of-approval/ 2025-01-06T01:22:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irx-010-immunorx-pharma-inflammation-likelihood-of-approval/ 2025-01-06T01:22:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vyd-2311-invivyd-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-06T01:22:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vebeglogene-autotemcel-lantu-biopharma-beta-thalassaemia-likelihood-of-approval/ 2025-01-06T01:22:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ql-401-qlsf-biotherapeutics-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-06T01:22:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ql-401-qlsf-biotherapeutics-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-06T01:22:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xb-010-exelixis-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-06T01:22:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/20nd02-hk-inno-n-glaucoma-likelihood-of-approval/ 2025-01-06T01:22:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-3454-chia-tai-tianqing-pharmaceutical-group-astrocytoma-likelihood-of-approval/ 2025-01-06T01:21:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cln-619-cullinan-therapeutics-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-06T01:20:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lomedeucitinib-bristol-myers-squibb-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2025-01-06T01:20:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-06T01:19:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sb-207-pelthos-therapeutics-genital-warts-condylomata-acuminata-likelihood-of-approval/ 2025-01-05T18:05:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gm-103-genemedicine-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-05T18:05:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-4052031-eli-lilly-and-co-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-05T18:05:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-4052031-eli-lilly-and-co-ovarian-cancer-likelihood-of-approval/ 2025-01-05T18:05:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ensifentrine-glycopyrrolate-verona-pharma-chronic-obstructive-pulmonary-disease-copd-likelihood-of-approval/ 2025-01-05T18:05:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sy-001-cellorigin-technology-hangzhou-pancreatic-cancer-likelihood-of-approval/ 2025-01-05T18:05:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aks-452-vakston-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T18:05:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/smart-101-smart-immune-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-05T18:05:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/smart-101-smart-immune-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-05T18:05:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6315-genentech-usa-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2025-01-05T18:05:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prgs-2-prg-s-tech-werner-syndrome-likelihood-of-approval/ 2025-01-05T18:05:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imp-1734-eikon-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-05T18:04:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ltx-608-talphera-disseminated-intravascular-coagulation-dic-likelihood-of-approval/ 2025-01-05T18:04:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ox-640-orexo-allergic-rhinitis-likelihood-of-approval/ 2025-01-05T18:04:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dvx-201-coeptis-therapeutics-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-05T18:04:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dvx-201-coeptis-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-05T18:04:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alm-223-almirall-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-05T18:04:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tp-05-tarsus-pharmaceuticals-lyme-disease-likelihood-of-approval/ 2025-01-05T18:04:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ebbh-2024-essen-biotech-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-05T18:04:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ns-136-neushen-therapeutics-psychosis-likelihood-of-approval/ 2025-01-05T18:04:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ccar-168-abelzeta-lupus-nephritis-likelihood-of-approval/ 2025-01-05T18:04:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cefiderocol-xeruborbactam-qpex-biopharma-gram-negative-bacterial-infections-likelihood-of-approval/ 2025-01-05T18:04:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thiscart7-suzhou-fundamenta-therapeutics-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-05T18:04:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-801-cytomx-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-05T18:04:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-801-cytomx-therapeutics-metastatic-melanoma-likelihood-of-approval/ 2025-01-05T18:04:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-admsc-allogeneic-hope-biosciences-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T18:03:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/benzalkonium-chloride-polyhexanide-turn-therapeutics-onychomycosis-tinea-unguium-likelihood-of-approval/ 2025-01-05T18:03:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ulecaciclib-aucentra-therapeutics-cervical-cancer-likelihood-of-approval/ 2025-01-05T18:03:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cyto-102-cytoimmune-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T18:03:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rct-2100-recode-therapeutics-cystic-fibrosis-likelihood-of-approval/ 2025-01-05T18:03:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cor-1389-corteria-pharmaceuticals-congestive-heart-failure-heart-failure-likelihood-of-approval/ 2025-01-05T18:03:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgbb-3227-beigene-gastrointestinal-tract-cancer-likelihood-of-approval/ 2025-01-05T18:03:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgbc-354-beigene-solid-tumor-likelihood-of-approval/ 2025-01-05T18:03:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tvgn-489-tevogen-bio-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T18:03:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tpx-107-tego-science-limbal-stem-cell-deficiency-lscd-likelihood-of-approval/ 2025-01-05T18:03:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/antivirals-covid-19-hiv-jcv-hbv-hcv-zika-ebola-palisades-therapeutics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T18:03:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mlt-103-meletios-therapeutics-viral-respiratory-tract-infection-likelihood-of-approval/ 2025-01-05T18:03:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yh-013-eucure-beijing-biopharma-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-05T18:03:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/telisotuzumab-adizutecan-abbvie-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-05T18:02:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/icovamenib-biomea-fusion-type-2-diabetes-likelihood-of-approval/ 2025-01-05T18:02:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/icovamenib-biomea-fusion-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2025-01-05T18:02:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naltrexone-la-biocorrx-alcohol-dependence-likelihood-of-approval/ 2025-01-05T18:02:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zp-9830-zealand-pharma-chronic-inflammation-likelihood-of-approval/ 2025-01-05T18:02:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cln-049-cullinan-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-05T18:02:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ulscs-restem-polymyositis-likelihood-of-approval/ 2025-01-05T18:02:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zofin-zeo-scientifix-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2025-01-05T18:02:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/telisotuzumab-adizutecan-abbvie-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-05T18:02:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/telisotuzumab-adizutecan-abbvie-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-05T18:02:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tvax-006-nanjing-yuandasai-weixin-biomedical-herpes-zoster-shingles-likelihood-of-approval/ 2025-01-05T18:02:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ans-014004-avistone-biotechnology-solid-tumor-likelihood-of-approval/ 2025-01-05T18:02:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/not-disclosed-neuroscience-and-pain-2-evotec-unspecified-neurologic-disorders-likelihood-of-approval/ 2025-01-05T18:02:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/monoclonal-antibody-to-inhibit-spike-glycoprotein-for-coronavirus-disease-2019-covid-19-jecho-biopharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T18:02:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gcc-4001-artiva-biotherapeutics-granulomatosis-with-polyangiitis-wegener-s-granulomatosis-likelihood-of-approval/ 2025-01-05T18:02:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/20nd02-hk-inno-n-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-05T18:01:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cor-101-corat-therapeutics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T18:01:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2025-01-05T18:01:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-162b1-biontech-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T18:01:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tb-006-truebinding-autism-spectrum-disorder-asd-likelihood-of-approval/ 2025-01-05T18:01:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/autologous-cultured-chondrocytes-biosolution-articular-cartilage-defect-likelihood-of-approval/ 2025-01-05T18:01:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvl-330-nuvalent-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T18:01:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ketorolac-tromethamine-levofloxacin-ntc-bacterial-conjunctivitis-likelihood-of-approval/ 2025-01-05T18:01:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zoryve-arcutis-biotherapeutics-psoriasis-likelihood-of-approval/ 2025-01-05T18:01:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senti-202-senti-biosciences-blood-cancer-likelihood-of-approval/ 2025-01-05T18:01:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexamethasone-sodium-phosphate-avm-biotechnology-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-05T18:01:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrnacr-04-gsk-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T18:01:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-24c5-lanova-medicines-gastric-cancer-likelihood-of-approval/ 2025-01-05T18:01:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regn-17092-regeneron-pharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T18:01:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/telisotuzumab-adizutecan-abbvie-gastric-cancer-likelihood-of-approval/ 2025-01-05T18:00:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gt-201-shanghai-grit-biotechnology-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-05T18:00:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sr-1375-shanghai-simr-biotech-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2025-01-05T18:00:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lx-2006-lexeo-therapeutics-cardiomyopathy-likelihood-of-approval-2/ 2025-01-05T18:00:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cr-1202-conaris-research-institute-unspecified-gastrointestinal-disorders-likelihood-of-approval/ 2025-01-05T18:00:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stx-478-scorpion-therapeutics-endometrial-cancer-likelihood-of-approval/ 2025-01-05T18:00:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imm-1-104-immuneering-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T18:00:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-admscs-hope-biosciences-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T18:00:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qxl-138am-nammi-therapeutics-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2025-01-05T18:00:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qxl-138am-nammi-therapeutics-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-05T18:00:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bw-20805-shanghai-argo-pharmaceutical-hereditary-angioedema-hae-c1-esterase-inhibitor-c1-inh-deficiency-likelihood-of-approval/ 2025-01-05T18:00:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/otov-101-suzhou-otovia-therapeutics-deafness-likelihood-of-approval/ 2025-01-05T18:00:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/influenza-vaccine-2-johnson-johnson-unspecified-influenza-virus-infections-likelihood-of-approval/ 2025-01-05T18:00:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eplivanserin-volinanserin-terran-biosciences-unspecified-psychiatric-disorders-likelihood-of-approval/ 2025-01-05T18:00:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brc-002-biopharmaceutical-research-complex-regional-pain-syndrome-sympathetic-reflex-dystrophy-reflex-sympathetic-dystrophy-likelihood-of-approval/ 2025-01-05T17:59:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ck-4015089-cytokinetics-muscular-dystrophy-likelihood-of-approval/ 2025-01-05T17:59:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-291-abbvie-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-05T17:59:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luag-06474-h-lundbeck-unspecified-neurologic-disorders-likelihood-of-approval/ 2025-01-05T17:59:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/r3r-01-river-3-renal-diabetic-nephropathy-likelihood-of-approval/ 2025-01-05T17:59:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imc-2017-immunecyte-spinal-cord-disorders-likelihood-of-approval/ 2025-01-05T17:59:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cilofexor-firsocostat-gilead-sciences-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-05T17:59:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cpl-409116-celon-pharma-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2025-01-05T17:59:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fecs-ad-s-biomedics-critical-limb-ischemia-likelihood-of-approval/ 2025-01-05T17:59:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeus-shield-t-wellington-zhaotai-therapies-liver-cancer-likelihood-of-approval/ 2025-01-05T17:59:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sysa-1801-elevation-oncology-esophageal-cancer-likelihood-of-approval/ 2025-01-05T17:59:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pm-54-pharma-mar-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-05T17:59:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pm-54-pharma-mar-castration-resistant-prostate-cancer-crpc-likelihood-of-approval/ 2025-01-05T17:59:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/covid-19-cd40-rbdv-linkinvax-europe-spas-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:59:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-aiviva-biopharma-diabetic-macular-edema-likelihood-of-approval/ 2025-01-05T17:58:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botulinum-toxin-huons-unspecified-musculoskeletal-disorders-likelihood-of-approval/ 2025-01-05T17:58:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/partnered-liquid-tumor-2-isogenica-hematological-tumor-likelihood-of-approval/ 2025-01-05T17:58:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-4178116-gsk-chicken-pox-likelihood-of-approval/ 2025-01-05T17:58:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dapagliflozin-biotts-type-2-diabetes-likelihood-of-approval/ 2025-01-05T17:58:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lvrna-009-aim-vaccine-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:58:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-gedeon-richter-post-menopausal-osteoporosis-likelihood-of-approval/ 2025-01-05T17:58:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pm-54-pharma-mar-esophageal-cancer-likelihood-of-approval/ 2025-01-05T17:58:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pm-54-pharma-mar-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:58:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psp-001-prosit-sole-biotechnology-beijing-norovirus-infections-likelihood-of-approval/ 2025-01-05T17:58:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuv-868-nuvation-bio-peritoneal-cancer-likelihood-of-approval/ 2025-01-05T17:58:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuv-868-nuvation-bio-pancreatic-cancer-likelihood-of-approval/ 2025-01-05T17:58:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-4101174-eli-lilly-and-co-prostate-cancer-likelihood-of-approval/ 2025-01-05T17:58:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrt-6160-monte-rosa-therapeutics-cutaneous-lupus-erythematosus-likelihood-of-approval/ 2025-01-05T17:58:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrt-6160-monte-rosa-therapeutics-psoriasis-likelihood-of-approval/ 2025-01-05T17:57:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abi-110-avirmax-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2025-01-05T17:57:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vax-nk-vaxcell-biotherapeutics-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:57:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/od-07656-odyssey-therapeutics-spondyloarthritis-spondyloarthropathy-likelihood-of-approval/ 2025-01-05T17:57:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/n-0877-eurofarma-laboratorios-idiopathic-essential-hypertension-likelihood-of-approval/ 2025-01-05T17:57:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ono-4915-ono-pharmaceutical-autoimmune-disorders-likelihood-of-approval/ 2025-01-05T17:57:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bg-570-sl-bigen-tuberculosis-likelihood-of-approval/ 2025-01-05T17:57:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-4101174-eli-lilly-and-co-ovarian-cancer-likelihood-of-approval/ 2025-01-05T17:56:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/primepro-thomas-advanced-medical-unspecified-cardiovascular-disorders-likelihood-of-approval/ 2025-01-05T17:56:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/primepro-thomas-advanced-medical-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:55:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gi-102-gi-innovation-solid-tumor-likelihood-of-approval/ 2025-01-05T17:55:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rq-01-red-queen-therapeutics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:42:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/phospholipid-modulator-boehringer-ingelheim-international-unspecified-ophthalmological-disorders-likelihood-of-approval/ 2025-01-05T17:42:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qtx-3046-quanta-therapeutics-lung-cancer-likelihood-of-approval/ 2025-01-05T17:42:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hpv-induced-cancers-theravectys-cervical-cancer-likelihood-of-approval/ 2025-01-05T17:41:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/csb-001-claris-biotherapeutics-keratitis-likelihood-of-approval/ 2025-01-05T17:41:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rec-01-purec-hypophosphatasia-likelihood-of-approval/ 2025-01-05T17:41:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mescaline-mind-medicine-mindmed-unspecified-psychiatric-disorders-likelihood-of-approval/ 2025-01-05T17:41:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/synkir-310-verismo-therapeutics-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-05T17:41:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/liver-sirna-nitto-biopharma-liver-cancer-likelihood-of-approval/ 2025-01-05T17:41:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bjtj-00012-beijing-tuojie-biomedical-technology-unspecified-metabolic-disorders-likelihood-of-approval/ 2025-01-05T17:41:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gip-glp-1-coagonist-iii-eli-lilly-and-co-cardiometabolic-disease-likelihood-of-approval/ 2025-01-05T17:41:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itu-512-novartis-sickle-cell-disease-likelihood-of-approval/ 2025-01-05T17:41:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-337-klus-pharma-solid-tumor-likelihood-of-approval/ 2025-01-05T17:41:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adx-097-q32-bio-inflammation-likelihood-of-approval/ 2025-01-05T17:41:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tt-01025-lg-chem-life-sciences-innovation-center-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-05T17:41:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cigb-2020-center-for-genetic-engineering-and-biotechnology-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:41:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fhd-909-foghorn-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:40:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tadalafil-united-laboratories-international-erectile-dysfunction-likelihood-of-approval/ 2025-01-05T17:40:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zg-802-zeria-pharmaceutical-hypoactive-bladder-likelihood-of-approval/ 2025-01-05T17:40:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6209-f-hoffmann-la-roche-unspecified-ophthalmological-disorders-likelihood-of-approval/ 2025-01-05T17:40:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986484-bristol-myers-squibb-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:40:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hm-001-hoist-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2025-01-05T17:40:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07940369-pfizer-anemia-likelihood-of-approval/ 2025-01-05T17:40:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gs-2121-gilead-sciences-solid-tumor-likelihood-of-approval/ 2025-01-05T17:40:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xav-19-xenothera-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2025-01-05T17:40:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/antibodies-for-coronavirus-disease-2019-covid-19-grifols-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:40:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pm-8002-biotheus-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:40:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/synkir-310-verismo-therapeutics-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-05T17:40:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tx-000045-tectonic-therapeutic-inc-congestive-heart-failure-heart-failure-likelihood-of-approval/ 2025-01-05T17:40:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-0036-huabo-biopharm-shanghai-melanoma-likelihood-of-approval/ 2025-01-05T17:40:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regenecyte-stemcyte-unspecified-hematological-disorders-likelihood-of-approval/ 2025-01-05T17:39:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regenecyte-stemcyte-post-acute-sequelae-of-covid-2019-pasc-or-long-covid-likelihood-of-approval/ 2025-01-05T17:39:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utaa09-17-gammadeltat-persongen-biotherapeutics-suzhou-follicular-lymphoma-likelihood-of-approval/ 2025-01-05T17:39:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-biosimilar-formycon-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:39:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syncar-001-stk-009-synthekine-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-05T17:39:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rs-1805-reistone-biopharma-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2025-01-05T17:39:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ql-401-qlsf-biotherapeutics-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-05T17:39:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibuprofen-loratadine-laboratorios-silanes-nasal-obstruction-likelihood-of-approval/ 2025-01-05T17:39:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tumor-infiltrating-lymphocytes-til-essen-biotech-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-05T17:39:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-5492-astrazeneca-follicular-lymphoma-likelihood-of-approval/ 2025-01-05T17:39:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irodanoprost-mesentech-duchenne-muscular-dystrophy-likelihood-of-approval/ 2025-01-05T17:39:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/autologous-suplexa-alloplex-biotherapeutics-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-05T17:39:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/autologous-suplexa-alloplex-biotherapeutics-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2025-01-05T17:39:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ptg-007-poltreg-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2025-01-05T17:39:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbx-12-cybrexa-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-05T17:38:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vilastobart-xilio-therapeutics-merkel-cell-carcinoma-likelihood-of-approval/ 2025-01-05T17:38:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vilastobart-xilio-therapeutics-gastric-cancer-likelihood-of-approval/ 2025-01-05T17:38:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-10188-beigene-esophageal-cancer-likelihood-of-approval/ 2025-01-05T17:38:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/universal-chimeric-antigen-receptor-modified-at19-cells-chengdu-usino-technology-biology-hematological-tumor-likelihood-of-approval/ 2025-01-05T17:38:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-1819479-boehringer-ingelheim-international-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-05T17:38:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vtx-2735-ventyx-biosciences-unspecified-cardiovascular-disorders-likelihood-of-approval/ 2025-01-05T17:38:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vbi-2905-vbi-vaccines-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:38:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utaa09-17-gammadeltat-persongen-biotherapeutics-suzhou-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-05T17:38:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cell-therapy-for-ischemic-heart-failure-and-non-ischemic-heart-failure-cell2cure-non-ischemic-cardiomyopathy-likelihood-of-approval/ 2025-01-05T17:38:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sa-58-sinovac-biotech-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:38:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prt-3789-prelude-therapeutics-esophageal-cancer-likelihood-of-approval/ 2025-01-05T17:38:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prt-3789-prelude-therapeutics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-05T17:38:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prt-3789-prelude-therapeutics-breast-cancer-likelihood-of-approval/ 2025-01-05T17:38:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/astx-295-taiho-pharmaceutical-malignant-pleural-mesothelioma-likelihood-of-approval/ 2025-01-05T17:37:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/astx-295-taiho-pharmaceutical-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-05T17:37:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hti-vaccine-aelix-therapeutics-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2025-01-05T17:37:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/covi-vac-codagenix-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:37:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dofetilide-hyloris-pharmaceuticals-atrial-flutter-likelihood-of-approval/ 2025-01-05T17:37:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osemitamab-transcenta-gastric-cancer-likelihood-of-approval/ 2025-01-05T17:37:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046040-pfizer-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-05T17:37:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maq-001-mabquest-solid-tumor-likelihood-of-approval/ 2025-01-05T17:37:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/scar-02-hunan-siweikang-therapeutics-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-05T17:37:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ro-7759065-genentech-usa-solid-tumor-likelihood-of-approval/ 2025-01-05T17:37:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sapanisertib-serabelisib-faeth-therapeutics-endometrial-cancer-likelihood-of-approval/ 2025-01-05T17:37:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-pd-1-vegf-bsab-3sbio-gynecological-cancer-likelihood-of-approval/ 2025-01-05T17:37:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gen-1184-genmab-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-05T17:37:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bh-30236-blossomhill-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-05T17:37:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hydroxychloroquine-pureims-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:37:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/londamocitinib-xinafoate-astrazeneca-asthma-likelihood-of-approval/ 2025-01-05T17:36:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dc-806-dice-therapeutics-unspecified-immunological-disorders-likelihood-of-approval/ 2025-01-05T17:36:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stem-cell-therapy-for-coronavirus-disease-2019-covid-19-stemedica-cell-technologies-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2025-01-05T17:36:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/slv-213-selva-therapeutics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:36:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrt-5410-sanofi-unspecified-influenza-virus-infections-likelihood-of-approval/ 2025-01-05T17:36:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tlc-6740-orsobio-type-2-diabetes-likelihood-of-approval/ 2025-01-05T17:36:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eb-103-estrella-immunopharma-follicular-lymphoma-likelihood-of-approval/ 2025-01-05T17:36:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hf-158k1-highfield-biopharmaceuticals-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval-2/ 2025-01-05T17:36:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lr-19155-lg-chem-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2025-01-05T17:36:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tele-bodor-laboratories-unspecified-ear-nose-throat-disorders-likelihood-of-approval/ 2025-01-05T17:36:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gcc-4001-artiva-biotherapeutics-pemphigus-vulgaris-likelihood-of-approval/ 2025-01-05T17:36:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046040-pfizer-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-05T17:36:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brl-201-brl-medicine-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval-2/ 2025-01-05T17:36:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onvapegleukin-alfa-ascendis-pharma-ovarian-cancer-likelihood-of-approval/ 2025-01-05T17:36:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pirfenidone-yungjin-pharm-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-05T17:35:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sysa-1801-elevation-oncology-gastric-cancer-likelihood-of-approval/ 2025-01-05T17:35:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gh-002-gh-research-unspecified-neurologic-disorders-likelihood-of-approval/ 2025-01-05T17:35:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mebufotenin-gh-research-unspecified-psychiatric-disorders-likelihood-of-approval/ 2025-01-05T17:35:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sodium-calcium-edetate-tobramycin-respirion-pharmaceuticals-pseudomonas-aeruginosa-infections-likelihood-of-approval/ 2025-01-05T17:35:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sodium-calcium-edetate-tobramycin-respirion-pharmaceuticals-cystic-fibrosis-likelihood-of-approval/ 2025-01-05T17:35:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apr-003-apros-therapeutics-liver-cancer-likelihood-of-approval/ 2025-01-05T17:35:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hf-158k1-highfield-biopharmaceuticals-cervical-cancer-likelihood-of-approval-2/ 2025-01-05T17:35:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-dnpm1-tcr-1-miltenyi-biomedicine-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-05T17:35:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvxcov-2540-novavax-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:35:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/viper-101-vittoria-biotherapeutics-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2025-01-05T17:35:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07934040-pfizer-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:35:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/smp-3124-sumitomo-pharma-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-05T17:35:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/smp-3124-sumitomo-pharma-uterine-cancer-likelihood-of-approval/ 2025-01-05T17:35:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sigvotatug-vedotin-pfizer-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-05T17:34:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imiquimod-zalifrelimab-urogen-pharma-prostate-cancer-likelihood-of-approval/ 2025-01-05T17:34:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6540-f-hoffmann-la-roche-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-05T17:34:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/geocm-04s1-geovax-labs-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:34:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalnicastobart-lyvgen-biopharma-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-05T17:34:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalnicastobart-lyvgen-biopharma-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-05T17:34:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-gene-therapy-indapta-therapeutics-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-05T17:33:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enb-104-ennovabio-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-05T17:33:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-05T17:33:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-cd22-car-kecellitics-biotech-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-05T17:33:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amelenodor-abbvie-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2025-01-05T17:33:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/son-1010-sonnet-biotherapeutics-solid-tumor-likelihood-of-approval/ 2025-01-05T17:33:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/clesacostat-tromethamine-ervogastat-pfizer-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-05T17:33:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gls-012-guangzhou-gloria-biosciences-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:33:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zt-002-beijing-ql-biopharmaceutical-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-05T17:33:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sti-103-sentynl-therapeutics-muscle-spasticity-likelihood-of-approval/ 2025-01-05T17:33:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-001-longbio-pharma-suzhou-anemia-likelihood-of-approval/ 2025-01-05T17:33:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalnicastobart-lyvgen-biopharma-solid-tumor-likelihood-of-approval/ 2025-01-05T17:33:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tak-861-takeda-pharmaceutical-unspecified-neurologic-disorders-likelihood-of-approval/ 2025-01-05T17:33:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-4101174-eli-lilly-and-co-esophageal-cancer-likelihood-of-approval/ 2025-01-05T17:33:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/smp-3124-sumitomo-pharma-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:32:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ebbh-2026-essen-biotech-t-cell-acute-lymphocytic-leukemia-t-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2025-01-05T17:32:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/met-097-metsera-obesity-likelihood-of-approval/ 2025-01-05T17:32:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrt-5421-sanofi-unspecified-influenza-virus-infections-likelihood-of-approval/ 2025-01-05T17:32:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-05T17:32:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-05T17:32:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-131-crispr-therapeutics-follicular-lymphoma-likelihood-of-approval/ 2025-01-05T17:32:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shra-2102-jiangsu-hengrui-medicine-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:32:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hs-135-35pharma-diastolic-heart-failure-hfpef-likelihood-of-approval/ 2025-01-05T17:32:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/200-s-series-novel-combinations-dopamine-pathway-alto-neuroscience-unspecified-psychiatric-disorders-likelihood-of-approval/ 2025-01-05T17:32:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syncar-001-stk-009-synthekine-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-05T17:32:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syncar-001-stk-009-synthekine-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-05T17:32:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bcd-245-biocad-osteosarcoma-likelihood-of-approval/ 2025-01-05T17:32:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atsn-101-atsena-therapeutics-leber-congenital-amaurosis-lca-likelihood-of-approval/ 2025-01-05T17:32:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esonadogene-imvoparvovec-wuhan-neurophth-biological-technology-leber-s-hereditary-optic-neuropathy-leber-optic-atrophy-likelihood-of-approval/ 2025-01-05T17:31:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trientine-hydrochloride-innolife-amyloidosis-likelihood-of-approval/ 2025-01-05T17:31:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07826390-pfizer-solid-tumor-likelihood-of-approval/ 2025-01-05T17:31:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07826390-pfizer-colorectal-cancer-likelihood-of-approval/ 2025-01-05T17:31:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ebbh-2024-essen-biotech-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-05T17:27:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tx-103-fuzhou-tcelltech-biological-science-and-technology-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-05T17:27:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hpg-1860-hepagene-therapeutics-shanghai-primary-sclerosing-cholangitis-likelihood-of-approval/ 2025-01-05T17:27:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hsk-21542-sichuan-haisco-pharmaceutical-unspecified-toxic-disorders-likelihood-of-approval/ 2025-01-05T17:27:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fluzone-qiv-hd-sanofi-unspecified-influenza-virus-infections-likelihood-of-approval/ 2025-01-05T17:27:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vet3-t12-kalivir-immunotherapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-05T17:27:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vet3-t12-kalivir-immunotherapeutics-sarcomas-likelihood-of-approval/ 2025-01-05T17:27:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/st-1891-sention-therapeutics-hypothyroidism-likelihood-of-approval/ 2025-01-05T17:27:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/colulintide-eli-lilly-and-co-obesity-likelihood-of-approval/ 2025-01-05T17:27:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prt-3789-prelude-therapeutics-ovarian-cancer-likelihood-of-approval/ 2025-01-05T17:26:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rd-1301-nanjing-bioheng-biotech-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-05T17:26:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/simaravibart-contraria-biotech-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:26:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amilo-5mer-galmed-pharmaceuticals-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2025-01-05T17:26:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ax-8-axalbion-chronic-cough-likelihood-of-approval/ 2025-01-05T17:26:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalpiciclib-jiangsu-hengrui-medicine-well-differentiated-liposarcoma-likelihood-of-approval/ 2025-01-05T17:26:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/organ-dysfunction-mortality-bioaegis-therapeutics-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2025-01-05T17:26:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cdr-404-cdr-life-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:26:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-her2-her3-dendritic-cell-vaccine-northwest-biotherapeutics-metastatic-brain-tumor-likelihood-of-approval/ 2025-01-05T17:26:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crexavibart-ogalvibart-bristol-myers-squibb-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:26:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/svf-002-svenska-vaccinfabriken-produktion-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:26:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-biosimilar-amgen-metastatic-melanoma-likelihood-of-approval/ 2025-01-05T17:26:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dsp-2342-sumitomo-pharma-america-unspecified-psychiatric-disorders-likelihood-of-approval/ 2025-01-05T17:26:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pm-54-pharma-mar-malignant-pleural-mesothelioma-likelihood-of-approval/ 2025-01-05T17:26:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/moma-313-moma-therapeutics-metastatic-prostate-cancer-likelihood-of-approval/ 2025-01-05T17:26:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/molgramostim-sucralfate-hyaloronan-reponex-pharmaceuticals-venous-leg-ulcers-crural-ulcer-likelihood-of-approval/ 2025-01-05T17:25:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sepantronium-bromide-beijing-zhikangbo-medical-oncology-research-prostate-cancer-likelihood-of-approval/ 2025-01-05T17:25:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gorivitug-regeneron-pharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:25:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efineptakin-alfa-neoimmunetech-high-grade-glioma-likelihood-of-approval/ 2025-01-05T17:25:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agle-102-aegle-therapeutics-epidermolysis-bullosa-likelihood-of-approval/ 2025-01-05T17:25:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/knx-100-kinoxis-therapeutics-unspecified-psychiatric-disorders-likelihood-of-approval/ 2025-01-05T17:25:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pm-54-pharma-mar-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-05T17:25:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pm-54-pharma-mar-melanoma-likelihood-of-approval/ 2025-01-05T17:25:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ltse-2578-structure-therapeutics-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-05T17:25:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azelastine-hydrochloride-cebina-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:25:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ovx-033-osivax-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:25:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mvccov-1901-medigen-vaccine-biologics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:25:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/icp-332-innocare-pharma-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2025-01-05T17:25:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cibotercept-keros-therapeutics-pulmonary-arterial-hypertension-likelihood-of-approval/ 2025-01-05T17:25:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vtp-1000-barinthus-biotherapeutics-celiac-disease-likelihood-of-approval/ 2025-01-05T17:24:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/celecoxib-valacyclovir-hydrochloride-dogwood-therapeutics-post-acute-sequelae-of-covid-2019-pasc-or-long-covid-likelihood-of-approval/ 2025-01-05T17:24:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guselkumab-golimumab-johnson-johnson-psoriatic-arthritis-likelihood-of-approval/ 2025-01-05T17:24:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lvgp120duocar-t-cells-lentigen-technology-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2025-01-05T17:24:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xyf-19-xi-an-yufan-biotechnology-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-05T17:24:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qxl-138am-nammi-therapeutics-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-05T17:24:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabometyx-exelixis-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-05T17:24:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dt-2216-dialectic-therapeutics-hematological-tumor-likelihood-of-approval/ 2025-01-05T17:24:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07872411-pfizer-streptococcal-pneumonia-likelihood-of-approval/ 2025-01-05T17:24:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rt-301-suzhou-ruotai-pharmaceutical-technology-unspecified-infectious-diseases-likelihood-of-approval/ 2025-01-05T17:24:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qtx-3046-quanta-therapeutics-colorectal-cancer-likelihood-of-approval/ 2025-01-05T17:24:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aopns-042-aodh-lifesciences-unspecified-infectious-diseases-likelihood-of-approval/ 2025-01-05T17:24:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/np-101-novatek-pharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:24:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zen-3694-zenith-epigenetics-melanoma-likelihood-of-approval/ 2025-01-05T17:24:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eltanexor-karyopharm-therapeutics-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-05T17:23:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ub-312-vaxxinity-multiple-system-atrophy-msa-or-shy-drager-syndrome-or-multi-system-degeneration-likelihood-of-approval/ 2025-01-05T17:23:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guselkumab-golimumab-johnson-johnson-ulcerative-colitis-likelihood-of-approval/ 2025-01-05T17:23:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alveavax-alvea-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:23:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07836396-pfizer-unspecified-influenza-virus-infections-likelihood-of-approval/ 2025-01-05T17:23:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alta-2618-alterome-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-05T17:23:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hrs-5041-jiangsu-hengrui-medicine-prostate-cancer-likelihood-of-approval/ 2025-01-05T17:23:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ucb-4594-ucb-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2025-01-05T17:23:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ucb-4594-ucb-pancreatic-cancer-likelihood-of-approval/ 2025-01-05T17:23:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/remdesivir-suzhou-vigonvita-life-sciences-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:23:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-filament-health-major-depressive-disorder-likelihood-of-approval/ 2025-01-05T17:23:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-filament-health-substance-drug-abuse-likelihood-of-approval/ 2025-01-05T17:23:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rap-219-rapport-therapeutics-peripheral-neuropathic-pain-likelihood-of-approval/ 2025-01-05T17:23:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-621-kymera-therapeutics-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2025-01-05T17:23:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wsd-0628-wayshine-biopharma-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-05T17:22:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bc-3195-biocity-biopharma-metastatic-ovarian-cancer-likelihood-of-approval/ 2025-01-05T17:22:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trb-051-trex-bio-autoimmune-disorders-likelihood-of-approval/ 2025-01-05T17:22:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pb-1902-pegbio-opioid-induced-constipation-oic-likelihood-of-approval/ 2025-01-05T17:22:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ltx-608-talphera-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:22:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thiscart7-suzhou-fundamenta-therapeutics-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-05T17:22:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/convidecia-cansino-biologics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:22:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-10188-beigene-metastatic-melanoma-likelihood-of-approval/ 2025-01-05T17:22:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0780-astrazeneca-renal-failure-likelihood-of-approval/ 2025-01-05T17:22:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/autologous-suplexa-alloplex-biotherapeutics-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-05T17:22:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/autologous-suplexa-alloplex-biotherapeutics-bladder-cancer-likelihood-of-approval/ 2025-01-05T17:22:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pocenbrodib-hydrochloride-pathos-ai-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-05T17:22:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6540-f-hoffmann-la-roche-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2025-01-05T17:22:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adipose-tissue-derived-mesenchymal-stem-cells-celltex-therapeutics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:22:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dazostinag-sodium-takeda-pharmaceutical-paranasal-sinus-and-nasal-cavity-cancer-likelihood-of-approval/ 2025-01-05T17:22:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kblp-001-kobiolabs-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2025-01-05T17:21:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-vibostolimab-merck-melanoma-likelihood-of-approval/ 2025-01-05T17:21:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-801-cytomx-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-05T17:21:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inc-036-hk-inno-n-hypertension-likelihood-of-approval/ 2025-01-05T17:21:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gcc-4001-artiva-biotherapeutics-microscopic-polyangiitis-mpa-likelihood-of-approval/ 2025-01-05T17:21:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-rezetecan-jiangsu-hengrui-medicine-breast-cancer-likelihood-of-approval/ 2025-01-05T17:21:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ulscs-restem-dermatomyositis-likelihood-of-approval/ 2025-01-05T17:21:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wil-1901-whan-in-pharm-dementia-associated-with-alzheimer-s-disease-likelihood-of-approval/ 2025-01-05T17:21:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ck-0802-cellenkos-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2025-01-05T17:21:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vilastobart-xilio-therapeutics-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-05T17:21:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rimtoregtide-hightide-therapeutics-alcoholic-hepatitis-likelihood-of-approval/ 2025-01-05T17:21:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etanercept-biosimilar-mabxience-holding-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-05T17:21:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/egfr-bats-transtarget-gliosarcoma-likelihood-of-approval/ 2025-01-05T17:21:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/egfr-bats-transtarget-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-05T17:21:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zofin-zeo-scientifix-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:20:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zofin-zeo-scientifix-post-acute-sequelae-of-covid-2019-pasc-or-long-covid-likelihood-of-approval/ 2025-01-05T17:20:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glycovax-002-glycovax-pharma-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:17:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hyaluronidase-recombinant-human-pembrolizumab-merck-metastatic-melanoma-likelihood-of-approval/ 2025-01-05T17:17:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hyaluronidase-recombinant-human-pembrolizumab-merck-solid-tumor-likelihood-of-approval/ 2025-01-05T17:17:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gc-506-gracell-biotechnologies-gastric-cancer-likelihood-of-approval/ 2025-01-05T17:17:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cholecalciferol-risedronate-sodium-dongkook-pharmaceutical-osteoporosis-likelihood-of-approval/ 2025-01-05T17:16:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pm-8002-biotheus-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-05T17:16:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vax-001-aegis-life-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:16:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-10188-beigene-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-05T17:16:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/coronavirus-disease-2019-covid-19-vaccine-1-johnson-johnson-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:16:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ank-700-anokion-relapsing-remitting-multiple-sclerosis-rrms-likelihood-of-approval/ 2025-01-05T17:16:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itm-91-itm-isotope-technologies-munich-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-05T17:16:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linavonkibart-scholar-rock-colorectal-cancer-likelihood-of-approval/ 2025-01-05T17:16:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/br-101801-boryung-pharmaceutical-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2025-01-05T17:16:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regenecyte-stemcyte-unspecified-metabolic-disorders-likelihood-of-approval/ 2025-01-05T17:16:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rna-pol-ii-inhibitor-bacteria-hamlet-pharma-inflammation-likelihood-of-approval/ 2025-01-05T17:16:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ac-0699-accutar-biotechnology-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-05T17:16:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apg-808-apogee-therapeutics-unspecified-immunological-disorders-likelihood-of-approval/ 2025-01-05T17:16:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alec-04-alentis-therapeutics-nasopharyngeal-cancer-likelihood-of-approval/ 2025-01-05T17:15:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osemitamab-transcenta-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-05T17:15:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osemitamab-transcenta-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-05T17:15:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vilastobart-xilio-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-05T17:15:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-10188-beigene-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-05T17:15:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-10188-beigene-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-05T17:15:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gt-0002x-gene-therapy-research-institution-aromatic-l-amino-acid-decarboxylase-aadc-deficiency-likelihood-of-approval/ 2025-01-05T17:15:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cinrebafusp-alfa-pieris-pharmaceuticals-gynecological-cancer-likelihood-of-approval/ 2025-01-05T17:15:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cellular-immunotherapy-to-inhibit-pd-l1-for-oncology-immunitybio-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-05T17:15:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lysergic-acid-diethylamide-mind-medicine-mindmed-pain-likelihood-of-approval/ 2025-01-05T17:15:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilurgisertib-fumarate-incyte-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2025-01-05T17:15:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fluticasone-propionate-salmeterol-xinafoate-korea-united-pharm-chronic-obstructive-pulmonary-disease-copd-likelihood-of-approval/ 2025-01-05T17:15:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tnb-738-ancora-biotech-unspecified-metabolic-disorders-likelihood-of-approval/ 2025-01-05T17:15:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osemitamab-transcenta-gallbladder-cancer-likelihood-of-approval/ 2025-01-05T17:15:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osemitamab-transcenta-solid-tumor-likelihood-of-approval/ 2025-01-05T17:14:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osemitamab-transcenta-ovarian-cancer-likelihood-of-approval/ 2025-01-05T17:14:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mosedipimod-enzychem-lifesciences-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2025-01-05T17:14:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-benecyte-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2025-01-05T17:14:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mesenchymal-stem-cells-derived-exosomes-abelzeta-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2025-01-05T17:14:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tnb-738-ancora-biotech-autoimmune-disorders-likelihood-of-approval/ 2025-01-05T17:14:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zolacabtagene-autoleucel-bristol-myers-squibb-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-05T17:14:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enb-106-ennovabio-acute-renal-failure-arf-acute-kidney-injury-likelihood-of-approval/ 2025-01-05T17:14:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onvapegleukin-alfa-ascendis-pharma-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:14:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apsa-02-armata-pharmaceuticals-bacteremia-likelihood-of-approval/ 2025-01-05T17:14:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imdatifan-nikang-therapeutics-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-05T17:14:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibi-354-innovent-biologics-endometrial-cancer-likelihood-of-approval/ 2025-01-05T17:14:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alloprime-mirror-biologics-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:14:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/coronavirus-disease-2019-covid-19-influenza-vaccine-pfizer-unspecified-influenza-virus-infections-likelihood-of-approval/ 2025-01-05T17:14:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jcxh-221-immorna-hangzhou-biotechnology-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:13:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-benecyte-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-05T17:13:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-benecyte-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-05T17:13:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuc-7738-nucana-metastatic-melanoma-likelihood-of-approval/ 2025-01-05T17:13:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-cervical-cancer-likelihood-of-approval/ 2025-01-05T17:13:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gm-103-genemedicine-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-05T17:13:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/meplazumab-jiangsu-pacific-meinuoke-bio-pharmarceutical-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval/ 2025-01-05T17:13:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cyt-108-cytonics-osteoarthritis-likelihood-of-approval/ 2025-01-05T17:13:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/epinephrine-ars-pharmaceuticals-food-allergy-likelihood-of-approval/ 2025-01-05T17:13:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/troculeucel-nkgen-biotech-alzheimer-s-disease-likelihood-of-approval/ 2025-01-05T17:13:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osemitamab-transcenta-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-05T17:13:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zolacabtagene-autoleucel-bristol-myers-squibb-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-05T17:13:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emp-012-empirico-inflammation-likelihood-of-approval/ 2025-01-05T17:13:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ksp-1007-meropenem-sumitomo-pharma-complicated-intra-abdominal-infections-likelihood-of-approval/ 2025-01-05T17:12:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eb-103-estrella-immunopharma-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-05T17:12:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ramatroban-kare-biosciences-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:12:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gm-103-genemedicine-head-and-neck-cancer-likelihood-of-approval/ 2025-01-05T17:12:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/purinostat-mesylate-chengdu-zenitar-biomedical-technology-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2025-01-05T17:12:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hx-009-waterstone-hanxbio-metastatic-melanoma-likelihood-of-approval/ 2025-01-05T17:12:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-05T17:12:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gm-103-genemedicine-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-05T17:12:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hx-009-waterstone-hanxbio-solid-tumor-likelihood-of-approval/ 2025-01-05T17:12:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ensomafusp-alfa-f-hoffmann-la-roche-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-05T17:12:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nuc-7738-nucana-lymphoma-likelihood-of-approval/ 2025-01-05T17:12:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/galicaftor-sionna-therapeutics-cystic-fibrosis-likelihood-of-approval/ 2025-01-05T17:12:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asn-008-formation-bio-notalgia-paresthetica-likelihood-of-approval/ 2025-01-05T17:12:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asn-008-formation-bio-pruritus-likelihood-of-approval/ 2025-01-05T17:11:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imc-2032-immunecyte-premature-ageing-likelihood-of-approval/ 2025-01-05T17:11:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rbd-7022-suzhou-ribo-life-sciences-hyperlipidemia-likelihood-of-approval/ 2025-01-05T17:11:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trecondyv-medac-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-05T17:11:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irx-101-irenix-medical-eye-infections-likelihood-of-approval/ 2025-01-05T17:11:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lvrna-021-aim-vaccine-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:11:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yl-202-suzhou-medilink-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:11:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/viper-101-vittoria-biotherapeutics-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2025-01-05T17:11:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regn-14284-regeneron-pharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:11:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-penile-cancer-likelihood-of-approval/ 2025-01-05T17:11:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abo-1009dp-suzhou-abogen-biosciences-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:11:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/db-1310-duality-biologics-shanghai-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-05T17:11:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-131-crispr-therapeutics-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-05T17:11:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-colorectal-cancer-likelihood-of-approval/ 2025-01-05T17:10:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexamethasone-sodium-phosphate-avm-biotechnology-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2025-01-05T17:10:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ono-4685-ono-pharmaceutical-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2025-01-05T17:10:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-2056-johnson-johnson-innovative-medicine-tauopathies-likelihood-of-approval/ 2025-01-05T17:10:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stapokibart-keymed-biosciences-prurigo-likelihood-of-approval/ 2025-01-05T17:10:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-2056-johnson-johnson-innovative-medicine-alzheimer-s-disease-likelihood-of-approval/ 2025-01-05T17:10:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xyf-19-xi-an-yufan-biotechnology-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2025-01-05T17:10:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-131-crispr-therapeutics-t-cell-lymphomas-likelihood-of-approval/ 2025-01-05T17:10:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vet3-t12-kalivir-immunotherapeutics-uterine-cancer-likelihood-of-approval/ 2025-01-05T17:10:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-325-biontech-castration-resistant-prostate-cancer-crpc-likelihood-of-approval/ 2025-01-05T17:10:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-nasopharyngeal-cancer-likelihood-of-approval/ 2025-01-05T17:10:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nexi-001-neximmune-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-05T17:10:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elsunersen-praxis-precision-medicines-epileptic-encephalopathy-likelihood-of-approval/ 2025-01-05T17:10:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/broncho-vaxom-om-pharma-allergic-asthma-likelihood-of-approval/ 2025-01-05T17:10:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sbp-101-spark-biopharma-biliary-tumor-likelihood-of-approval/ 2025-01-05T17:09:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-325-biontech-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:09:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arommp-7-arrowhead-pharmaceuticals-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-05T17:09:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/renal-medullary-carcinoma-rmc-therapeutic-calviri-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2025-01-05T17:09:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lomvastomig-f-hoffmann-la-roche-metastatic-melanoma-likelihood-of-approval/ 2025-01-05T17:09:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/morf-057-eli-lilly-and-co-ulcerative-colitis-likelihood-of-approval/ 2025-01-05T17:09:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/monlunabant-inversago-pharma-hypertriglyceridemia-likelihood-of-approval/ 2025-01-05T17:09:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xyf-19-xi-an-yufan-biotechnology-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-05T17:09:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xyf-19-xi-an-yufan-biotechnology-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-05T17:09:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mirabegron-tamsulosin-hydrochloride-dongkoo-bio-pharma-overactive-bladder-likelihood-of-approval/ 2025-01-05T17:09:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xyf-19-xi-an-yufan-biotechnology-hairy-cell-leukemia-likelihood-of-approval/ 2025-01-05T17:09:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbx-12-cybrexa-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-05T17:09:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbx-12-cybrexa-gallbladder-cancer-likelihood-of-approval/ 2025-01-05T17:09:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vevoctadekin-simcha-therapeutics-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-05T17:08:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hu-444-180-life-sciences-pain-likelihood-of-approval/ 2025-01-05T17:08:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-solid-tumor-likelihood-of-approval/ 2025-01-05T17:08:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-relatlimab-bristol-myers-squibb-metastatic-uveal-melanoma-likelihood-of-approval/ 2025-01-05T17:08:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/delpacibart-zotadirsen-avidity-biosciences-duchenne-muscular-dystrophy-likelihood-of-approval/ 2025-01-05T17:08:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snv-calidi-biotherapeutics-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-05T17:08:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bat-8006-bio-thera-solutions-peritoneal-cancer-likelihood-of-approval/ 2025-01-05T17:08:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ai-071-oncoc4-acute-respiratory-failure-likelihood-of-approval/ 2025-01-05T17:08:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lr-20062-lg-chem-meningitis-likelihood-of-approval/ 2025-01-05T17:08:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bio-106-bionecure-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-05T17:08:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inbrx-106-inhibrx-biosciences-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-05T17:08:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anpa-0073-schrodinger-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-05T17:08:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/son-1010-sonnet-biotherapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:08:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brl-201-brl-medicine-diffuse-large-b-cell-lymphoma-likelihood-of-approval-2/ 2025-01-05T17:08:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgba-445-beigene-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-05T17:07:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obudanersen-sodium-ionis-pharmaceuticals-angelman-syndrome-likelihood-of-approval/ 2025-01-05T17:07:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enb-106-ennovabio-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-05T17:07:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nexi-001-neximmune-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-05T17:07:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/com-701-compugen-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-05T17:07:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosfomycin-disodium-meitheal-pharmaceuticals-pyelonephritis-likelihood-of-approval/ 2025-01-05T17:07:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nxe-0033744-nxera-pharma-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2025-01-05T17:07:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qxl-138am-nammi-therapeutics-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-05T17:07:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qxl-138am-nammi-therapeutics-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2025-01-05T17:07:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1230-moderna-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:07:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aqa-0325-aquavit-pharmaceuticals-unspecified-neurologic-disorders-likelihood-of-approval/ 2025-01-05T17:07:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aqc-001-aquavit-pharmaceuticals-unspecified-neurologic-disorders-likelihood-of-approval/ 2025-01-05T17:07:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/akt-022-aquavit-pharmaceuticals-unspecified-dermatological-disorders-likelihood-of-approval/ 2025-01-05T17:07:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nyprg-101-ceruvia-lifesciences-opium-opioid-addiction-likelihood-of-approval/ 2025-01-05T17:06:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dorocubicel-excellthera-blood-cancer-likelihood-of-approval/ 2025-01-05T17:06:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kls-2031-kolon-life-science-radiculopathy-likelihood-of-approval/ 2025-01-05T17:06:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yl-13027-shanghai-yingli-pharmaceutical-solid-tumor-likelihood-of-approval/ 2025-01-05T17:06:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ds-1103-integral-molecular-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-05T17:06:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/autologous-suplexa-alloplex-biotherapeutics-solid-tumor-likelihood-of-approval/ 2025-01-05T17:06:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cannabidiol-1-cardiol-therapeutics-pericarditis-likelihood-of-approval/ 2025-01-05T17:06:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/frevecitinib-kinaset-therapeutics-chronic-obstructive-pulmonary-disease-copd-likelihood-of-approval/ 2025-01-05T17:06:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dpxe-7-biovaxys-technology-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-05T17:06:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-angiosarcoma-likelihood-of-approval/ 2025-01-05T17:06:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enb-104-ennovabio-inflammatory-bowel-disease-likelihood-of-approval/ 2025-01-05T17:06:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olmesartan-amlodipine-rosuvastatin-ezetimibe-daewoong-pharmaceutical-hypercholesterolemia-likelihood-of-approval/ 2025-01-05T17:06:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegtarazimod-realta-life-sciences-coronavirus-disease-2019-covid-19-associated-acute-lung-injury-likelihood-of-approval/ 2025-01-05T17:06:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/astx-295-taiho-pharmaceutical-uveal-melanoma-likelihood-of-approval/ 2025-01-05T17:06:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/astx-295-taiho-pharmaceutical-solid-tumor-likelihood-of-approval/ 2025-01-05T17:05:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cu-06-curacle-ulcerative-colitis-likelihood-of-approval/ 2025-01-05T17:05:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tebapivat-agios-pharmaceuticals-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-05T17:05:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-69968054-johnson-johnson-escherichia-coli-infections-likelihood-of-approval/ 2025-01-05T17:05:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mivelsiran-sodium-alnylam-pharmaceuticals-unspecified-central-nervous-system-disorders-likelihood-of-approval/ 2025-01-05T17:05:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jadicell-covid-19-therapeutic-solutions-international-coronavirus-disease-2019-covid-19-associated-acute-lung-injury-likelihood-of-approval/ 2025-01-05T17:05:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-peritoneal-cancer-likelihood-of-approval/ 2025-01-05T17:05:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/buprenorphine-sr-indivior-opium-opioid-addiction-likelihood-of-approval/ 2025-01-05T17:05:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amlitelimab-sanofi-celiac-disease-likelihood-of-approval/ 2025-01-05T17:05:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fenretinide-laurent-pharmaceuticals-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:05:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lbt-3627-longevity-biotech-parkinson-s-disease-likelihood-of-approval/ 2025-01-05T17:05:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/appa-02-armata-pharmaceuticals-bronchiectasis-likelihood-of-approval/ 2025-01-05T17:05:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rapcabtagene-autoleucel-novartis-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2025-01-05T17:05:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sgr-3515-schrodinger-solid-tumor-likelihood-of-approval/ 2025-01-05T17:05:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sco-240-scohia-pharma-growth-hormone-deficiency-likelihood-of-approval/ 2025-01-05T17:04:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brequinar-clear-creek-bio-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:04:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acasunlimab-biontech-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:04:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gm-103-genemedicine-cervical-cancer-likelihood-of-approval/ 2025-01-05T17:04:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hx-009-waterstone-hanxbio-biliary-tumor-likelihood-of-approval/ 2025-01-05T17:04:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hx-009-waterstone-hanxbio-sarcomas-likelihood-of-approval/ 2025-01-05T17:04:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fhl-101-forest-hills-partners-hong-kong-unspecified-neurologic-disorders-likelihood-of-approval/ 2025-01-05T17:04:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belantamab-mafodotin-gsk-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-05T17:04:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utidelone-biostar-pharmaceuticals-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:04:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eg-009-shenzhen-evergreen-therapeutics-coronavirus-disease-2019-covid-19-associated-cytokine-release-syndrome-likelihood-of-approval/ 2025-01-05T17:04:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dvx-201-coeptis-therapeutics-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-05T17:04:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gs-441524-copycat-sciences-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:04:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dnth-103-dianthus-therapeutics-chronic-inflammatory-demyelinating-polyneuropathy-cidp-likelihood-of-approval/ 2025-01-05T17:04:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gen-001-genome-co-gastric-cancer-likelihood-of-approval/ 2025-01-05T17:03:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/central-nervous-system-disorders-neuroplast-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2025-01-05T17:03:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ts-161-taisho-pharmaceutical-major-depressive-disorder-likelihood-of-approval/ 2025-01-05T17:03:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elasomeran-imelasomeran-moderna-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:03:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guselkumab-golimumab-johnson-johnson-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2025-01-05T17:03:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pomalidomide-qilu-pharmaceutical-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-05T17:03:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cg-spikedown-caregen-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:03:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vanzacaftor-calcium-deutivacaftor-tezacaftor-vertex-pharmaceuticals-cystic-fibrosis-likelihood-of-approval/ 2025-01-05T17:03:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalutrafusp-alfa-agenus-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-05T17:03:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jab-3068-jacobio-pharmaceuticals-group-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:03:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabometyx-exelixis-salivary-gland-cancer-likelihood-of-approval/ 2025-01-05T17:03:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dazostinag-sodium-takeda-pharmaceutical-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-05T17:03:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linavonkibart-scholar-rock-prostate-cancer-likelihood-of-approval/ 2025-01-05T17:03:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sp-0230-sanofi-neisseria-meningitidis-infections-likelihood-of-approval/ 2025-01-05T17:03:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zb-004-zenas-biopharma-usa-autoimmune-disorders-likelihood-of-approval/ 2025-01-05T17:02:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/universal-chimeric-antigen-receptor-modified-at19-cells-chengdu-usino-technology-biology-unspecified-b-cell-lymphomas-likelihood-of-approval/ 2025-01-05T17:02:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gen-1184-genmab-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-05T17:02:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lipisense-lipigon-pharmaceuticals-cardiometabolic-disease-likelihood-of-approval/ 2025-01-05T17:02:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vevoctadekin-simcha-therapeutics-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-05T17:02:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/revumenib-citrate-syndax-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2025-01-05T17:02:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ad-17002-advagene-biopharma-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:02:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/int-102-intact-therapeutics-ulcerative-colitis-likelihood-of-approval/ 2025-01-05T17:02:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snb-101-sn-bioscience-rectal-cancer-likelihood-of-approval/ 2025-01-05T17:02:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vevoctadekin-simcha-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-05T17:02:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ak-119-akaal-pharma-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2025-01-05T17:02:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emraclidine-cerevel-therapeutics-psychosis-likelihood-of-approval/ 2025-01-05T17:02:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/norketotifen-emergo-therapeutics-unspecified-influenza-virus-infections-likelihood-of-approval/ 2025-01-05T17:02:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/scg-142-scg-cell-therapy-human-papillomavirus-hpv-associated-cancer-likelihood-of-approval/ 2025-01-05T17:02:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alphaf-001-alpha-fusion-papillary-thyroid-cancer-likelihood-of-approval/ 2025-01-05T17:01:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osvid-19-osvah-pharmaceutical-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:01:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imp-1734-eikon-therapeutics-peritoneal-cancer-likelihood-of-approval/ 2025-01-05T17:01:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amt-676-multitude-therapeutics-pancreatic-ductal-carcinoma-likelihood-of-approval/ 2025-01-05T17:01:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retlirafusp-alfa-jiangsu-hengrui-medicine-gastric-cancer-likelihood-of-approval/ 2025-01-05T17:01:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lomvastomig-f-hoffmann-la-roche-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:01:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vutiglabridin-glaceum-age-related-macular-degeneration-likelihood-of-approval/ 2025-01-05T17:01:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rulonilimab-shandong-new-time-pharmaceutical-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-05T17:01:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vepdegestrant-arvinas-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-05T17:01:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ineo-vac-p01-hangzhou-neoantigen-therapeutics-esophageal-cancer-likelihood-of-approval/ 2025-01-05T17:01:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gen-1184-genmab-malignant-mesothelioma-likelihood-of-approval/ 2025-01-05T17:01:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gen-1184-genmab-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:01:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vmt-a-net-perspective-therapeutics-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-05T17:01:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exo-cd24-nano24med-coronavirus-disease-2019-covid-19-likelihood-of-approval/ 2025-01-05T17:01:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nx-210c-axoltis-pharma-relapsing-remitting-multiple-sclerosis-rrms-likelihood-of-approval/ 2025-01-05T17:00:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nx-210c-axoltis-pharma-parkinson-s-disease-likelihood-of-approval/ 2025-01-05T17:00:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eplontersen-sodium-astrazeneca-familial-amyloid-cardiomyopathy-likelihood-of-approval/ 2025-01-05T17:00:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anv-419-anaveon-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-05T17:00:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bitr-2101-boston-immune-technologies-and-therapeutics-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-05T17:00:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nxp-800-nuvectis-pharma-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-05T17:00:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ion-283-ionis-pharmaceuticals-lafora-disease-unverricht-disease-likelihood-of-approval/ 2025-01-05T17:00:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xyf-19-xi-an-yufan-biotechnology-burkitt-lymphoma-likelihood-of-approval/ 2025-01-05T17:00:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vir-5818-vir-biotechnology-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-05T17:00:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sotorasib-amgen-solid-tumor-likelihood-of-approval/ 2025-01-05T17:00:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anv-419-anaveon-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-05T17:00:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-19-shanghai-yake-biotechnology-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-05T17:00:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-fungal-zambon-co-fungal-respiratory-tract-infections-likelihood-of-approval/ 2025-01-05T17:00:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anhydrous-enol-oxaloacetate-metvital-fatigue-likelihood-of-approval/ 2025-01-05T17:00:01+00:00 daily 0.2